
HER2 tyrosine kinase inhibitorIndian prescription status not found in lists checkedJan Aushadhi listed
Lapatinib
लापाटिनिब
This page covers the tablets form only, as described in the EU product information. Other forms of lapatinib sold in India may differ.
Lapatinib is a tablet for adults with breast cancer whose tumours overexpress HER2. It is used with other cancer medicines. The label warns that it can lower heart pumping function, so heart checks are needed before and during treatment. Ask your doctor or pharmacist before use.
- Generic name
- Lapatinib
- Used for
- Treating HER2-positive breast cancer, together with capecitabine, trastuzumab or an aromatase inhibitor.
- Label used
- EU product information (EMA EPAR tyverb), retrieved 2026-10-15
- Prescription status (India)
- Not found in the Schedule H/H1/X/G lists we checked
- On NLEM 2022
- Not found in the list we checked
- NPPA price ceiling
- Not listed in the lists we checked
More facts
- Jan Aushadhi
- Listed (1 product row)
- Banned combinations
- None found in the list we checked
Compiled from official drug labels and Indian government sources. Always follow your doctor's or pharmacist's advice.
Safety at a glance
- AlcoholNot mentioned in label text
- PregnancyAvoid, per label textSee wording
- BreastfeedingAvoid, per label textSee wording
- DrivingNot mentioned in label text
- KidneyNot mentioned in label text
- LiverNot mentioned in label text
Taken only from the label text cited on this page. "Not mentioned" does not mean safe. Ask your doctor or pharmacist.
What is lapatinib used for?
The label we reviewed (an EU product information text) describes lapatinib for adults with breast cancer whose tumours overexpress HER2.
It is used only in combination: with capecitabine, with trastuzumab, or with an aromatase inhibitor, depending on the stage and type of disease.
- Advanced or metastatic HER2-positive breast cancer after earlier therapy, with capecitabine
- Hormone receptor-negative metastatic disease, with trastuzumab
- Postmenopausal hormone receptor-positive metastatic disease, with an aromatase inhibitor
Lapatinib is a cancer tablet used with other medicines for HER2-positive breast cancer.
Source1
How does lapatinib work?
Lapatinib blocks two enzymes, EGFR and HER2, inside cancer cells. These enzymes send signals that help tumour cells grow.
By blocking them, the medicine slows the growth of tumour cells that depend on these signals.
It blocks growth signals inside HER2-positive cancer cells.
Source1
How is lapatinib usually taken?
This page covers the tablets label only (route: ). Dosing for other forms differs, and the prescriber decides which one you use.
This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.
This page covers the tablet. The label says treatment should be started by a doctor experienced in cancer medicines, and HER2 status must be confirmed with validated tests.
The label describes a once-daily, continuous dose that differs by the partner medicine: one level with capecitabine, another with trastuzumab, and a higher level with an aromatase inhibitor. Your doctor sets the exact number of tablets.
The label describes stopping or lowering the dose if heart function falls or other serious reactions occur. Capecitabine is taken with food or within 30 minutes after food.
- Taken once daily, continuously
- Dose depends on the combination partner
- Doctor may pause or lower the dose for side effects
- Capecitabine, if used, goes with food
Dose depends on which medicine it is paired with, and your cancer doctor decides it.
Source1
What are the side effects of lapatinib?
Common
- The label says the most common reactions (more than 25%) were diarrhoea, nausea, vomiting and rash. Palmar-plantar erythrodysesthesia (sore, red palms and soles) was common with capecitabine.
- Diarrhoea, nausea, vomiting
- Rash
- Sore red palms and soles (with capecitabine)
- Lower heart pumping function
- QTc prolongation
Serious: get help
- Serious effects include a fall in left ventricular ejection fraction (heart pumping), which was severe in some cases and fatal cases were reported, and a QTc interval increase on heart tracings.
Common effects are diarrhoea, nausea and rash; heart function can fall.
Source1
Who should be careful with lapatinib?
The label says heart function (LVEF) should be checked before starting and during treatment. Caution is advised in people with conditions that could weaken the left ventricle or who take other medicines that can harm the heart.
The label advises caution with QTc prolongation risk. The only listed contraindication is hypersensitivity to the active substance or excipients.
The label says women who could become pregnant should use adequate contraception and avoid pregnancy during treatment and for at least 5 days after the last dose. It should not be used in pregnancy unless clearly necessary. Safe use in breastfeeding has not been established.
- Heart function checks before and during treatment
- Caution if QTc interval is a concern
- Not for use if hypersensitive to it
- Avoid pregnancy; use contraception
- Breastfeeding not established
Heart function must be checked, and pregnancy should be avoided.
Source1
What medicines interact with lapatinib?
- Strong CYP3A4 inhibitors (for example ketoconazole, ritonavir)
- CYP3A4 inducers (for example rifampicin, carbamazepine, St John's Wort)
- Drugs that can harm the heart or lengthen QTc
- The label says lapatinib is mainly broken down by CYP3A.
- Strong CYP3A4 inhibitors such as ritonavir, ketoconazole, itraconazole and voriconazole should be avoided, and moderate inhibitors need caution.
- Strong CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin and St John's Wort should be avoided because they can lower lapatinib levels.
No match in this label text. Ask your pharmacist about any medicine you take.
Some antifungals, antivirals, and seizure or TB medicines change its levels.
Source1
How should lapatinib be stored?
The label text we reviewed gives no storage temperature for this product.
Follow the storage line on your own pack, and keep medicines out of the reach of children.
Follow the storage instructions on your pack.
Source1
Is lapatinib a prescription medicine in India?
We did not find lapatinib in the Drugs Rules 1945 Schedule H, H1, X or G rows we checked, so we cannot state its Indian prescription status from our lists. Ask your pharmacist or doctor.
We did not find lapatinib on the National List of Essential Medicines 2022 in the list we checked.
The Jan Aushadhi (PMBJP) list we checked has 1 product row that mention lapatinib. We did not capture prices for them.
We did not find lapatinib in the Schedule H, H1, X or G rows we checked, not found on NLEM 2022.
Source2
What is the price ceiling for lapatinib?
Jan Aushadhi lists lapatinib products including Lapatinib Tablets IP 250mg 250mg. We have not shown a price for them. Check the pack and the seller for the actual price.
NPPA lists per-unit ceilings where a formulation is scheduled. Check the pack and seller.
Source2
Frequently asked questions
Can I drink alcohol while taking lapatinib?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Is lapatinib safe in pregnancy and breastfeeding?
The label says it should not be used in pregnancy unless clearly necessary, and safe use in breastfeeding is not established. Ask your doctor or pharmacist.
Source1
Should lapatinib be taken with food?
The label describes food timing only for capecitabine, its partner medicine. For lapatinib itself, ask your doctor or pharmacist.
Source1
Can lapatinib affect driving or alertness?
The label we reviewed does not say in the text provided. Ask your doctor or pharmacist.
Source1
Can children or older adults take lapatinib?
The label describes use in adults. It does not describe use in children in the text provided. Ask your doctor or pharmacist.
Source1
Is lapatinib on the NLEM and Jan Aushadhi list?
We did not find it on NLEM 2022. Yes, several lapatinib products are in the Jan Aushadhi list we checked.
Source2
Sources
- 1EMA European Public Assessment Report: product information (EU) (tyverb) Open source · 2026-10-15
- 2PMBJP (Jan Aushadhi) product list (p70:sno1536) Open source · 2026-10-15
Compiled by software from the sources above and checked by automated rules. Last checked: 2026-10-15 · How we use sources · Report a correction
This information is educational and is not a substitute for advice from your doctor or pharmacist. It does not tell you what dose you personally should take. In an emergency call 112.